Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors

Journal of Medicinal Chemistry

Volumn 41, Issue 23, 1998, Pages 4453-4465

  Marot, Christophe ^a   Chavatte, Philippe ^b   Morin Allory, Luc ^a   Viaud, Marie Claude ^a   Guillaumet, Gérald ^a   Renard, Pierre ^c   Lesieur, Daniel ^b   Michel, André ^d  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b Institut de Chimie Pharmaceutique   (France)

^c ADIR   (France)

^d INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 IODOMELATONIN; LIGAND; MELATONIN; MELATONIN RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; HORMONE RECEPTOR INTERACTION; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PINEAL BODY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SHEEP;

ANIMALS; BRAIN; LIGANDS; MELATONIN; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN; REPRODUCIBILITY OF RESULTS; SHEEP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032487939     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980026p     Document Type: Article

References (32)

1. Lerner, A. B.; Case, J. D.; Heinzelman, R. V. Structure of melatonin. J. Am. Chem. Soc. 1959, 81, 6084-6085.
2. Miles, A.; Philbrick, D. R. S.; Thomson, C. Melatonin: Clinical perspectives; Oxford Medical Publications; Oxford University Press: Oxford, 1988.
3. Cagnacci, A. Melatonin in relation to physiology in adult humans. J. Pineal Res. 1996, 21, 200-213.
4. Brugger, P.; Marktl, W.; Herold, M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995, 345, 1408-1415.
5. Reiter, R. J. Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Front. Neuroendocrinol. 1995, 16, 383-415.
6. Reiter, R. J. Antioxidant actions of melatonin. Adv. Pharmacol. 1997, 38, 1103-117.
7. Dawson, D.; Encel, N. Melatonin and sleep in humans. J. Pineal Res. 1993, 15, 1-12.
8. Ebisawa, T.; Karne, S.; Lerner, M. R.; Reppert, S. M. Expression cloning of a high affinity melatonin receptor from Xenopus dermal melanophores. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 6133-6137.
9. Reppert, S. M.; Weaver, D. R.; Godson, C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci. 1996, 17, 100-102.
10. 1A receptor: Contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models J. Med. Chem. 1996, 39, 126-134.
11. Cramer, R. D. III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
12. Yous, S.; Andrieux, J.; Howell, H. E.; Morgan, P.; Renard, P.; Pfeiffer, B.; Lesieur, D.; Guardiola-Lemaitre, B. Novel Naphatalenic Ligands with High Affinity for the Melatonin Receptor. J. Med. Chem. 1992, 35, 1484-1486.
13. Depreux, P.; Lesieur, D.; Ait Mansour, H.; Morgan, P.; Howell, H. E.; Renard, P.; Caignard, D. H.; Pfeiffer, B.; Delagrange, P.; Guardioln, B.; Yous, S.; Demarque, A.; Adam, G.; Andrieux, J. Synthesis and Structure-Activity Relationships of Novel Naphthalenic and Bioisosteric Related Amidic Derivatives as Melatonin Receptor Ligands. J. Med. Chem. 1994, 37, 3231-3239.
14. 125I]IodoMelatonin Binding Site. J. Med. Chem. 1995, 38, 2050-2060.
15. Garratt, P. J.; Travard, S.; Vonhoff, S. Mapping the Melatonin Receptor. 4. Comparison of the Binding Affinities of a Series of Substitued Phenylalkyl Amides. J. Med. Chem. 1996, 39, 1797-1805.
16. Mathé-Allainmat, M.; Gaudy, F.; Sicsic, S.; Dangy-Caye, A. L.; Shen, S.; Brémont, B.; Benatalah, Z.; Langlois, M.; Renard, P.; Delagrange, P. Synthesis of 2-amido-2,3-dihydro-1H-phenalene Derivatives as New conformationally Restricted Ligands for Melatonin Receptor. J. Med. Chem. 1996, 39, 3089-3095.
17. Leclerc, V.; Depreux, P.; Lesieur, D.; Caignard, D. H.; Renard, P.; Delagrange, P.; Guardiola-Lemaitre, B.; Morgan, P. Synthesis and Biological Activity of Conformationally Restricted Tricyclic Analogs of the Hormone Melatonin. Bioorg. Med. Chem. Lett. 1996, 6, 1071-1076.
18. Sicsic, S.; Serraz, I.; Andrieux, J.; Brémont, B.; Mathé-Allainmat, M.; Poncet, A.; Shen, S.; Langlois, M. 3D Quantitative Structure-Activity Relationship of Melatonin Receptor Ligands: A Comparative Molecular Field Analysis Study. J. Med. Chem. 1997, 40, 739-748.
19. Viaud, M. C.; Mamai, A.; Guerin, V.; Bennejean, C.; Renard, P.; Delagrange, P.; Guardiola-Lemaitre, B.; Howell, H. E.; Guillaumet, G. Substitued 3-amido and 3-amidoalkylbenzopyran Derivatives: Synthesis and Pharmacological Activity as Melatonin Ligands. Pharm. Sci., submitted.
20. Mazeas, D.; Viaud, M. C.; Guillaumet, G. Synthesis of Azaindolic Derivatives as Melatonin Analogs. Fourth European Conference of Groupement des Pharmacochimistes de l'Arc Atlantique, Glasgow (Ecosse), 10-11 September 1996.
21. Morgan, P. J.; Lawson, M.; Davidson, G.; Howell, H. E. Melatonin inhibits cyclic AMP production in cultured ovine pars tuberalis cells. J. Mol, Endocrinol. 1989, 5, 3-8.
22. Morgan, P. J.; Williams, L. M.; Davidson, G.; Lawson, M.; Howell, H. E. Melatonin receptors on ovine pars tuberalis: characterization and autoradiographical localization. J. Neuroendocrinol. 1989, 1, 1-4.
23. SYBYL 6.2, Tripos Associates, Inc., St. Louis, MO.
24. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
25. Stewart, J. J. P. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-103.
26. Audry, E.; Dubost, J. P.; Dallet, P.; Langlois, M. H.; Colleter, J. C. The Molecular Lipophilic Potential: Application to a series of beta-adrenolytic amines. Eur. J. Med. Chem. 1989, 24, 155-161.
27. (a) Gaillard, P.; Carrupt, P. A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a toll in 3D-QSAR. Method and Applications. J. Comput.-Aided Mol. Des. 1994, 8, 83-96.
28. (b) Institut of medicinal Chemistry, University of Lausanne, BEP CH-1015 Lausanne, Switzerland.
29. Simon, Z. Comparative molecular field analysis. Critical components. Rev. Roum. Chim. 1992, 37, 323-325.
30. Folkers, G.; Merz, A.; Rogman, D. CoMFA: scope and limitations. In 3D QSAR in Drug Design, Theory Methods and Applications; Kubinyi, H., Ed.; ESCOM Science Publishers: Leiden, 1993; pp 593-618.
31. Van de Waterbeemd, H.; Testa, B. The parametrization of lipophilicity and other structural properties in drug design. In Advances in Drug Research; Testa, B., Ed.; Academic Press: London, 1987; Vol. 16, pp 87-227.
32. Spadoni, G.; Balsamini, C.; Diamantini, G.; Di Giacomo, B.; Tarzia, G. Conformationally Restrained Melatonin Analogues: Synthesis, Binding Affinity for the Melatonin Receptor, Evaluation of the Biological Activity and Molecular Modeling Study. J. Med. Chem. 1997, 40, 1990-2002.